Peanut blood-fat signature linked to 11% lower diabetes risk

They applied the score to the EPIC-Potsdam study, which followed adults in Germany. The analysis included 774 people who developed type 2 diabetes and 547 who developed cardiovascular disease, diseases affecting the heart and blood vessels.

Each one-standard-deviation increase—a statistical step reflecting how much the scores vary—was associated with an 11% lower risk of type 2 diabetes. The score showed no association with cardiovascular disease.

Takeaway: A blood-based pattern linked to peanut consumption also tracked with lower diabetes risk, but not with cardiovascular disease.

What role did body weight play?

Body mass index (BMI), a common measure of weight relative to height, appeared to account for most of the diabetes association. The researchers used a mediation analysis—a statistical check of how much another variable might explain an association—to assess BMI’s role.

That pattern suggests peanuts may help partly by influencing weight. However, the researchers called the analysis hypothesis-generating, meaning it identifies a possible explanation that requires further testing, and they reported wide uncertainty.

The trial’s six-month duration and 63-person sample of healthy young adults also leave long-term effects and applicability to other groups uncertain.

Takeaway: Body weight was the leading explanation for the diabetes link, but the evidence did not settle the mechanism.

What can dietitians take from the study?

The authors frame the findings as support for peanuts as a source of healthy fats within a diet that protects heart and metabolic health. Their conclusion connected the trial’s blood-fat changes with the later diabetes association:

“Peanut consumption induces changes in the circulating lipidome, largely involving very long-chain saturated fatty acid-containing lipids, which are associated with lower type 2 diabetes risk partly through BMI,” the scientists concluded.

They also said the results highlight peanuts as a source of dietary fats that may be linked to lower risk of type 2 diabetes.

For dietitians and other practitioners, the study identifies a specific blood-fat response to peanuts, then associates that response with lower diabetes risk. It does not turn the 11% figure into a guaranteed individual benefit or establish peanuts as a diabetes treatment.

Inés Domínguez-López and colleagues published the work as “Peanuts-derived plasma lipids and lower risk of type 2 diabetes: association mediated by body mass index — an intervention and case-cohort study.” It appeared in The American Journal of Clinical Nutrition, volume 124, issue 5, article 101527 (2026), with DOI 10.1016/j.ajcnut.2026.101527.

Bottom line: Peanuts changed blood fats in the trial, and the trial signature tracked with lower type 2 diabetes risk; body weight was the leading, but still unproven, explanation.